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The new era in medical research and development, based
on new approaches and advanced technologies, enabled
profound insights, in various levels and degrees of sensi-
tivity, on the human body physical and mental function-
ing. The identification of these micro and macro
environmental factors created a real need for new analy-
sis tools and translational models. The “big data” created
and harvested in health care, from the molecular to the
physiological, imaging and environmental data, etc, cre-
ated an inevitable growing need for sophisticated analysis
tools. “In 10 years each individual will be surrounded by
a virtual cloud of billions of data pointsP4 medicine”
1. More than that there is a need to provide a broad
understanding on the all factors interplay, based on com-
bining all relevant data sources and utilizing all available
analysis tools. New technologies are developed to har-
vest, verify, control, transfer, align and transform data, as
well as new innovative analysis and predictive targeted
tools to meet these challenges, both in academia and
industry. In parallel there is a growing need to new inno-
vative and sophisticated tools to analyse “small data”.
That is to enable reliable and responsible preventive,
predictive and personalized medicine, in most cases
where there is more data than equivalent records. New
philosophical approaches, as well as innovative analysis
tools, specially developed to meet these challenges, must
be taken, based on the coupling of computer sciences,
complexity theory, non linear dynamics, logic theory, etc.
That is in compliance and in parallel to the statistical
models such as generalized linear models or classification
trees that are further endowed by new regularization
methods, as well as recent developments in FDR (False
Discovery Rate) testing emphasizing the hierarchical
structure.
A targeted data mining tools will be presented to com-
ply with the real need to deal with all interplay of all fac-
tors originated in different sources, such as: molecular,
genetics, images, physiology, etc, presented in different
scales. More than that the goal is to analyze small sets of
data containing many parameters, including missing
values. The presented patented rule discovery and predic-
tion data mining tool, enables the simultaneous analysis
of multilevel, multisource data (imaging, signals, categori-
cal, numerical and descriptive data) as is, with no data
manipulation, such as normalization, or neglecting part
of the data. The goal is to relate to the whole data set
as is, while handling missing data - which is one of the
major needs in providing the whole system approach.
The algorithm reveals the underlying rules while attaching
a level of confidence to each rule, identifies the unexpected
rules and detects the unexpected cases. Furthermore the
tool was found to be less sensitive to over- fitting (small
sets with many parameters).
In summary the Data Mining and prediction tool is
proven to reveal all If Than rules, all If than Not rules
and a subset of If and Only If (necessary and sufficient
conditions) tools, with no prior assumptions. Three
detailed examples will be presented. The evaluation of
the Epoetin adverse effects to assess long term risks and
advancing towards better Epoetin driven treatment
modalities, based on the survival analysis of dialysis
patients and cardiovascular patients treated with EPO.
The second example will deal with dementia and neuro-
degenerative combined data taken from the hospital
practice (MCI, AD and normal patients) to evaluate and
optimize the various treatments and provide accurate
predictions. The third example deals with the analysis of
the progression of disease in ALS patients based on the
patient s current disease status. The data mining tool
was already successfully applied to other applications
such as: autoimmune diseases, drug development,Correspondence: miram@post.tau.ac.il
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personalized skin treatment, skin genetic data and bio-
markers analysis, etc.
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